Core Viewpoint - The company, Haiseng Medical, has successfully listed on the Beijing Stock Exchange, focusing on the research and manufacturing of anesthesia and monitoring medical consumables, establishing itself as a leading enterprise in this sector in China [1][3]. Company Overview - Haiseng Medical is recognized as a national-level specialized and innovative "little giant" enterprise, with a product matrix that includes anesthesia, monitoring, surgical, and nursing categories [1]. - The company has developed 14 core technologies that form a strong technical moat for its product matrix, including innovations in pressure sensors, signal acquisition, and various medical device manufacturing processes [6]. Financial Performance - The company reported significant revenue growth driven by its core technologies, with revenues from these products reaching 2.23 billion, 2.54 billion, 2.53 billion, and 1.32 billion from 2022 to the first half of 2025, accounting for over 83% of its main business income during these periods [6]. - The company has established stable relationships with major clients, achieving sales coverage across all 31 provinces, autonomous regions, and municipalities in China, as well as exporting to key international markets [6]. Market Position - Haiseng Medical is positioned as a leading enterprise in the anesthesia and monitoring medical consumables sector, with a competitive edge reflected in its product offerings and technological advancements [3][6]. - The company has a market capitalization of 1 billion yuan, with an issue price of 12.64 yuan per share [3]. Investment Direction - The company plans to allocate raised funds primarily towards upgrading and expanding production capacity for emergency medical devices (1.74 billion yuan, 46.95%), establishing a research and testing center (1.39 billion yuan, 37.52%), and building a marketing service base (0.58 billion yuan, 15.54%) [3]. Challenges - Haiseng Medical faces the risk of production capacity saturation, as its existing capacity is nearing full utilization. Without timely expansion, the company may struggle to meet the growing market demand, potentially hindering its future growth [7].

Investment Rating - The report does not explicitly state an investment rating for the company. Core Insights - Haisheng Medical is recognized as a national-level specialized and innovative "little giant" in the field of anesthesia and monitoring medical devices, with a comprehensive product offering and strong market presence in China [3][18]. - The company has a solid growth trajectory, with revenue expected to reach 304 million yuan in 2024, a slight decrease of 0.70% year-on-year, but showing positive growth in the first three quarters of 2025 with a revenue increase of 19.89% [3][12]. - The company has a robust technology matrix with 63 patents, including 13 invention patents, and has undertaken numerous significant technology projects at various governmental levels [3][18]. Company Overview - Haisheng Medical specializes in anesthesia and monitoring medical devices, serving major clinical departments such as anesthesia, ICU, and emergency [3][15]. - The company has established a strong brand and marketing network, with products used in over 600 top-tier hospitals, including prestigious institutions like Peking Union Medical College Hospital [5][12]. - The revenue composition for 2024 indicates that anesthesia products account for 52.60%, monitoring products for 36.59%, and surgical and nursing products for 10.47% [30][33]. Financial Performance - In 2024, the company is projected to achieve a gross margin of 52.09% and a net margin of 23.35% [12][30]. - The net profit attributable to the parent company for 2024 is expected to be approximately 70.92 million yuan, reflecting a year-on-year decline of 9.12% [12][30]. - The company’s R&D expenses for 2024 are estimated at 16.16 million yuan, representing 5.32% of revenue, with a year-on-year growth of 21.67% in the first three quarters of 2025 [5][12]. Industry Analysis - The medical device market in China is rapidly growing, with the market size expected to increase from 440.3 billion yuan in 2017 to 1.1544 trillion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 14.76% [4][18]. - The low-value medical consumables market is projected to reach 185.2 billion yuan in 2024, with a year-on-year growth of 19.49% [4][30]. - The global medical device industry is also on an upward trend, with the market size expected to grow from 479.36 billion USD in 2023 to 637.96 billion USD by 2028 [4][18]. Competitive Position - Haisheng Medical's performance in terms of revenue growth is superior compared to its peers, with the company leading in revenue CAGR among comparable companies from 2022 to 2024 [12][14]. - The company has established a strong competitive edge through its proprietary technologies and extensive patent portfolio, which includes critical innovations in blood pressure sensors and bioelectrical signal acquisition [5][12].